# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001213900-26-031552
**Filing Date:** 2026-3
**Character Count:** 10321
**Document Hash:** 0b9b08e9549eadc024ddb55608bc0e10
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-031552.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001213900-26-031552

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260319

**FILED AS OF DATE**: 20260319

**DATE AS OF CHANGE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 26772451

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. [333-251073](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm), [333-248980](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) and [333-228671](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)) and our Registration Statements on Form F-3 (Files No. [333-274816](http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm), [333-251647](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm), [333-231417](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) and [333-250076](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm))**

**ALTERITY THERAPEUTICS LIMITED**

**(a development stage enterprise)**

The following exhibits are submitted:

99.1 [Proposed issue of securities - ATH](ea028258001ex99-1.htm)

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| By: | /s/ Julian Babarczy |
|  | Julian Babarczy |
|  | Chairman |

---

Date: March 19, 2026

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](ea028258001_ex99-1img1.jpg) | Appendix 3B - Proposed issue of securities |

---

Announcement Summary

**Entity name**

ALTERITY THERAPEUTICS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

19/3/2026

**The Proposed issue is:**

A placement or other type of issue

**Total number of +securities proposed to be issued for a placement or other type of issue**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**ASX +security code** | &nbsp;&nbsp;**+Security description** | &nbsp;&nbsp;**Maximum Number of**<br> **+securities to be issued** |
| &nbsp;&nbsp;New class-code to be confirmed | &nbsp;&nbsp;Options with expiry date five (5) years after date of issue and exercise price of A$0.02. | &nbsp;&nbsp;150000000 |

---

**Proposed +issue date**

26/6/2026

Refer to next page for full details of the announcement

Appendix 3B - Proposed issue of securities 1/5

---

| | |
|:---|:---|
| ![](ea028258001_ex99-1img1.jpg) | Appendix 3B - Proposed issue of securities |

---

Part 1 - Entity and announcement details

---

| |
|:---|
| **1.1 Name of +Entity** |
| ALTERITY THERAPEUTICS LIMITED |
| We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.<br> If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation). |

---

---

| | |
|:---|:---|
| **1.2 Registered Number Type** | **Registration Number** |
| ABN | 37080699065 |

---

---

| |
|:---|
| **1.3 ASX issuer code** |
| ATH |
| **1.4 The announcement is** |
| New announcement |
| **1.5 Date of this announcement** |
| 19/3/2026 |
| **1.6 The Proposed issue is:** |
| A placement or other type of issue |

---

Appendix 3B - Proposed issue of securities 2/5

---

| | |
|:---|:---|
| ![](ea028258001_ex99-1img1.jpg) | Appendix 3B - Proposed issue of securities |

---

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

**7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?**

Yes

7A.1a Conditions

---

| | | | |
|:---|:---|:---|:---|
| **Approval/Condition** | **Date for determination** | **Is the date estimated or**<br> **actual?** | **\*\* Approval**<br> **received/condition met?** |
| +Security holder approval | 27/5/2026 | Estimated |  |

---

**Comments**

Part 7B - Issue details

---

| | |
|:---|:---|
| **Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?** <br> New class | **Will the proposed issue of this +security include an offer of attaching +securities?**<br> No |

---

Details of +securities proposed to be issued

**ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)**

---

| | |
|:---|:---|
| **Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?** <br> **No** | **Will the entity be seeking quotation of the 'new' class of +securities on ASX?**<br> No |

---

---

| | |
|:---|:---|
| **ASX +security code** | **+Security description** |
| New class-code to be confirmed | Options with expiry date five (5) years after date of issue and exercise price of A$0.02. |

---

**+Security type** 

Options

**Number of +securities proposed to be issued** 

150,000,000

Appendix 3B - Proposed issue of securities 3/5

---

| | |
|:---|:---|
| ![](ea028258001_ex99-1img1.jpg) | Appendix 3B - Proposed issue of securities |

---

**Offer price details**

**Are the +securities proposed to be issued being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

No consideration provided.

**Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.0000001 **Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

Options details

---

| | | |
|:---|:---|:---|
| **+Security currency** | **Exercise price** | **Expiry date** |
| AUD - Australian Dollar | AUD 0.0200 | 26/6/2031 |

---

**Details of the type of +security that will be issued if the option is exercised**

ATH : ORDINARY FULLY PAID

**Number of securities that will be issued if the option is exercised**

One fully paid ordinary share (ASX:ATH)

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities**

**proposed to be issued or provide the information by separate announcement.**

To be provided in the future Notice of Meeting announcement.

Part 7C - Timetable

**7C.1 Proposed +issue date 2**

26/6/2026

Part 7D - Listing Rule requirements

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?**

Yes

**7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1**

27/5/2026

**7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?**

Yes

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

Appendix 3B - Proposed issue of securities 4/5

---

| | |
|:---|:---|
| ![](ea028258001_ex99-1img1.jpg) | Appendix 3B - Proposed issue of securities |

---

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

Part 7E - Fees and expenses

**7E.1 Will there be a lead manager or broker to the proposed issue?**

No

**7E.2 Is the proposed issue to be underwritten?**

No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

Part 7F - Further Information

**7F.01 The purpose(s) for which the entity is issuing the securities**

Payment for services rendered for Lawrence Gozlan and Julian Babarczy.

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**

Appendix 3B - Proposed issue of securities 5/5